3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
7
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm, Residual
1
Estrogen Receptor-positive Breast Cancer
1
Endometrial Endometrioid Adenocarcinoma
1
Brain Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
pembrolizumab
3
atezolizumab
2
trametinib
1
sargramostim
1
ruxolitinib
1
reolysin
1
poly(I).poly(c12,U)
1
poly ICLC
1
neratinib
1
incomplete Freund's adjuvant
1
glembatumumab vedotin
1
epigallocatechin gallate
1
entinostat
1
dupilumab
1
Zymosan
1
Zinc
1
Watchful Waiting
1
Vaccines
1
Uridine Monophosphate
1
Trastuzumab
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Quercetin
1
Positron-Emission Tomography
1
Paclitaxel
1
Neurofibromin 2
1
Neoadjuvant Therapy
1
Metformin
1
Leukapheresis
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Triple Negative Breast Neoplasms
×
Letrozole
×
Clear all
NCT04102618
2022-08-15
AWARE-1
Oncolytics Biotech
Phase EARLY_PHASE1
Terminated
26 enrolled